



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Docket No.: 2923-508

SCHMITT et al

Customer No.: 6449

Serial Number: 09/926,323

Group Art Unit: 1642

Filed: March 5, 2002

Examiner: L. Helms

For: DIAGNOSTIC AND THERAPEUTIC USE OF ANTIBODIES AGAINST THE
UROKINASE RECEPTOR

STATEMENT UNDER 37 C.F.R. § 1.821(C)

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

February 17, 2004

Sir:


In accordance with 37 C.F.R. § 1.821(C), applicant is submitting herewith the
Sequence Listing for the above-identified application in computer readable form.

The name of the file on the computer readable form is 2923.508. The disk is
identical to the attached paper copy.

In the event this paper is not being timely filed, the applicant respectfully
petitions for an appropriate extension of time.


Please charge any fee deficiency or credit any overpayment to Deposit
Account No. 02-2135.

Respectfully submitted,

By 

Monica Chin Kitts
Attorney for Applicants
Registration No. 36,105
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202)783-6040

MK/cg



**UNITED STATES DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office**

Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

09/926323

EXAMINER

L.H. Helms

ART UNIT	PAPER
----------	-------

1642

20031124

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

1. The response filed 10/24/03 will be held in abeyance until this application is in sequence compliance. The response filed 10/24 added claims reciting SEQ ID NO: 5 and 6, however this application does not have these sequences in the sequence listing.

Therefore, this application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth above.

2. Any inquiry concerning this communication should be directed to Examiner Larry R. Helms, Ph.D, Art Unit 1642, whose telephone number is (703) 306-5879.

3. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

4. Any questions regarding compliance with the sequence rules requirements specifically should be directed to the departments listed at the bottom of the Notice to Comply.

5. APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

EXAMINER
Larry R. Helms Ph.D.

LARRY R. HELMS, PH.D.
PRIMARY EXAMINER